TrophiPatch cell patch for chronic diabetic and venous leg ulcers

Allogenic Adipose-derived Stromal Cell Patch (i.e TrophiPatch, Provided by HekeTiss®) for Chronic Leg Ulcers Resistant to Standard Treatment: Safety and Preliminary Efficacy, a One-arm Monocentric Phase I-ll Trial

We will try a one-time donor-derived adipose stromal cell patch (TrophiPatch) to help heal chronic diabetic foot or venous leg ulcers in adults.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University Hospital, Geneva (Academic / other)
• Locations: 1 site (Geneva)
• Trial ID: NCT07048054 on ClinicalTrials.gov

What this trial studies

TrophiPatch is an allogeneic adipose-derived stromal cell patch applied once to a selected index ulcer in each participant. Eighteen adults with chronic diabetic foot ulcers or hard-to-heal venous leg ulcers will be enrolled and followed for up to 24 weeks with about 23 scheduled visits for monitoring. The product contains purified donor stromal cells processed in a certified laboratory and is intended to promote wound healing through anti-inflammatory and pro-angiogenic effects observed in preclinical studies. This Phase 1/2 study focuses on safety and preliminary signals of efficacy in a small, closely monitored cohort.

Who should consider this trial

Good fit: Adults with a chronic diabetic foot ulcer or a venous leg ulcer that has been hard to heal—typically 5–25 cm² in area and with less than 40% area reduction during a four-week run-in (for VLU)—who can consent and attend frequent follow-up visits are the intended participants.

Not a fit: Patients with clinically infected wounds, significant arterial insufficiency, ulcers outside the specified size or duration windows, or those unable to attend frequent visits may be unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, TrophiPatch could speed healing of chronic leg ulcers, reduce prolonged wound care needs, and lower risks such as infection or amputation.

How similar studies have performed: Early-phase and preclinical work with adipose-derived stromal cells and similar cell-based dressings have shown promising signs of improved wound healing, but larger randomized trials are still limited.

Eligibility criteria

Inclusion Criteria

* Age 18 years or older.
* Patients with more than one eligible ulcer will have one - usually the largest or more clinically significant - selected at screening as the index ulcer.
* Participants will have the capacity to understand study procedures, and will be able to providewritten informed consent.

(for VLU only)

* Diagnosed with at least one venous leg ulcer.
* Ulcers duration for 6 weeks to 3 years at the time of screening.
* Hard-to-healed ulcers with cross-sectional area that have decreased by less than 40% during a four-week run-in period.
* Reference ulcer surface from 5 to 25 cm2.
* At the time of inclusion, the ulcer will be clinically non-infected (TILI score ≥ 5).
* Absence of significant arterial insufficiency assessed at clinical examination (intermittent claudication or resting pain, necrotic or distal wound on the foot) and systolic homolateral ankle-brachial index (ABI) greater than 0.75 and inferior to 1.40 or biphasic or triphasic Doppler signals in the dorsalis or posterior tibial arteries of the affected limb.

(for DFU only)

* Patient with type 1 or type 2 diabetes.
* Diagnosed with at least one diabetic foot ulcer on a foot or both feet below the level of the malleoli, excluding ulcers confined to the interdigital cleft.
* Ulcers duration for 4 weeks to 3 years at the time of screening.
* Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50% during a four-week run-in period.
* Reference ulcer surface from 1 to 25 cm2.
* At the inclusion, the ulcer will be clinically non-infected (according to IDSA criteria).
* HbA1C \< 12% at screening.
* Absence of significant arterial insufficiency assessed by systolic homolateral ankle-brachial index (ABI) greater than 0.75 and inferior to 1.40 or biphasic or triphasic Doppler signals in the dorsalis or posterior tibial arteries of the affected limb.

Exclusion Criteria

* Subject has a history of:

  * endstage renal disease
  * uncontrolled cardiac failure
  * severe malnutrition
  * severe liver disease
  * aplastic anemia
  * malignant disease (active or recent (\<5 years))diabetes avec HbA1C \> 12%
  * rheumatoid arthritis
  * sickle cell disease
  * other connective tissue disorder
  * irradiation to the affected extremity
* Serum creatinine concentration greater than 180 umol/L and/or receipt of renal dialysis or an estimated glomerular filtration rate (based on cystatin C or serum creatinine) of less than 20 mL/min per 1·73 m²
* Drug or alcohol abuse.
* Limited physical capacity or total immobility.
* Known pregnancy or nursing at the time of screening visit
* Subject is currently receiving (i.e within 30 days prior to inclusion) or scheduled to receive a medication or treatment that, in the opinion of the investigator, will interfere with or affect the rate of wound healing.
* Index ulcers probing to tendon, muscle, capsule and bone.
* Local or systemic signs of ongoing infection.
* Hypersensitivity to silicone or porcine gelatin.
* Previous treatment with growth factors, stem cells, or an equivalent preparation within the 8 weeks before the baseline visit.
* Involvement in another interventional clinical trial within the 4 weeks before the baseline visit.
* Known or suspected absence of capacity to understand the study procedures or provide written informed consent (decided by the investigator).
* Cross-sectional area of the index ulcer had increased by at least 20%.

(for VLU only)

* History of poor compliance with compression therapy.
* Presence of peripheral neuropathy of the lower limbs.

(for DFU only)

• History of poor compliance with offloading therapy.

Where this trial is running

Geneva

• University Hospitals of Geneva — Geneva, Switzerland (Recruiting)

Study contacts

• Study coordinator: Nicolo C Brembilla, Dr

Conditions Diabetic Foot Ulcer; Venous Leg Ulcer